KMT2A and acute lymphoblastic leukemia: Together with our previous work, demonstrating that HDAC inhibition effectively and specifically targets MLL-rearranged ALL both in vitro and in vivo [15], this opens further treatment possibilities for infant ALL, such as irinotecan and HDAC inhibitor combination therapy, potentially reducing dosages and/or alleviating treatment regimens.